- Home
- ELPC vs TGTX Comparison
ELPC vs TGTX Comparison
Compare ELPC & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELPC
- TGTX
- Stock Information
- Founded
- ELPC 1954
- TGTX 1993
- Country
- ELPC Brazil
- TGTX United States
- Employees
- ELPC N/A
- TGTX N/A
- Industry
- ELPC Electric Utilities: Central
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- ELPC Utilities
- TGTX Health Care
- Exchange
- ELPC Nasdaq
- TGTX Nasdaq
- Market Cap
- ELPC 6.1B
- TGTX 5.5B
- IPO Year
- ELPC N/A
- TGTX 1995
- Fundamental
- Price
- ELPC $10.12
- TGTX $31.33
- Analyst Decision
- ELPC
- TGTX Strong Buy
- Analyst Count
- ELPC 0
- TGTX 5
- Target Price
- ELPC N/A
- TGTX $48.20
- AVG Volume (30 Days)
- ELPC 2.5K
- TGTX 2.0M
- Earning Date
- ELPC 01-01-0001
- TGTX 11-03-2025
- Dividend Yield
- ELPC 3.96%
- TGTX N/A
- EPS Growth
- ELPC 30.24
- TGTX N/A
- EPS
- ELPC 0.19
- TGTX 2.78
- Revenue
- ELPC $4,381,150,343.00
- TGTX $531,898,000.00
- Revenue This Year
- ELPC N/A
- TGTX $82.31
- Revenue Next Year
- ELPC $6.83
- TGTX $49.05
- P/E Ratio
- ELPC $14.12
- TGTX $11.17
- Revenue Growth
- ELPC 8.47
- TGTX 100.88
- 52 Week Low
- ELPC $5.04
- TGTX $25.28
- 52 Week High
- ELPC $10.51
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- ELPC 63.97
- TGTX 39.54
- Support Level
- ELPC $8.73
- TGTX $29.80
- Resistance Level
- ELPC $10.51
- TGTX $34.74
- Average True Range (ATR)
- ELPC 0.19
- TGTX 1.76
- MACD
- ELPC 0.04
- TGTX -0.43
- Stochastic Oscillator
- ELPC 78.09
- TGTX 23.21
About ELPC Companhia Paranaense de Energia (COPEL) (each representing four (4))
Cia Paranaense De Energia Copel is engaged in the areas of generation, transmission, commercialization and distribution of energy. It operates a comprehensive and effective electrical system with its own generating plants, transmission lines, substations, electrical lines and grids of the distribution system. The company's reportable segments include Power generation and transmission, Power distribution, GAS, Power sale, Services, and Holding. The majority of its revenue is generated from the Power generation and transmission segment under which it produces electricity from hydraulic, wind, and thermal projects and provides services of transmission and transformation of electric power and other related services.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.